Age-Related Macular Degeneration
Conditions
Keywords
AMD, age-related macular degeneration, geographic atrophy, GA
Brief summary
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.
Detailed description
Age-related macular degeneration (AMD) results in severe, irreversible central vision loss and is the leading cause of blindness in individuals older than 50 years in the western world. The vast majority of AMD patients have the 'dry' (non-exudative) form that is characterized by the presence of drusen and atrophic changes in the retinal pigment epithelium (RPE). Dry AMD may remain static or progress slowly to produce areas of geographic atrophy (GA), the advanced or late-stage form of dry AMD. GA is a severe vision-threatening lesion of the macula that may impair visual function, impact daily life activities, and result in blindness. Currently, there is no approved treatment for dry AMD or GA. Pre-clinical results have shown that OT-551 may protect RPE cells and photoreceptors from oxidative damage and block angiogenesis stimulated by VEGF and other growth factors, and therefore is a therapeutic candidate for treating GA.
Interventions
DRUGOT-551
OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
DRUGvehicle placebo
OT-551 0% ophthalmic solution, 2 drops 4 times daily
Sponsors
Othera Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* have a clinical diagnosis of GA in one or both eyes; * be of non-childbearing potential
Exclusion criteria
* have GA secondary to any condition other than AMD in the study eye; * have a BCVA of 20/200 or worse in the non-study eye; * have a history of or current choroidal neovascularization in either eye, or the need for any study eye anti-angiogenic therapy; * have any ocular condition in the study eye that would progress during the course of the study and could affect central vision or other ocular conditions that may be a confounding factor in this study; * need to wear contact lenses in the study eye during the study; * had confounding ocular surgery in the study eye; * have concomitant treatment with any systemic or ocular medication that is known to be toxic to the lens, retina, or optic nerve;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the area of GA | 2 years |
Countries
United States
Outcome results
None listed